Second-line therapy in testicular germ cell tumours: results from a tertiary cancer care centre in India.
TIP
second line therapy
testicular cancer
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
10
2021
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Malignant testicular neoplasms constitute about 1% of all cancers in males. This is one of the most common tumours in adolescents and young adult males. After the introduction of cisplatin-based chemotherapy, the survival of germ cell tumour patients, even those with poor prognostic risk factors, has significantly improved over the years. Second-line chemotherapy in patients who have progressed over the first-line cisplatin-based chemotherapy has shown convincing 5 years of overall survival (OS). This study is a retrospective analysis of testicular cancer patients from 2014 to 2020 who have received salvage chemotherapy treatment at Tata Memorial Centre. Patient demographics, tumour characteristics and treatment details were recorded in a specific format, and progression-free survival and OS were analysed along with response to therapy. A total of 46 testicular cancer patients from 2014 to 2020, who received second-line chemotherapy, were analysed from the database maintained at our hospital. The median age at diagnosis was 29.5 (18-60) years. Most of the patients (30, 65.2%) presented with lung metastasis and 11 (23.9%) patients with liver metastasis. Most of the patients (21, 45.6%) received vinblastine, ifosfamide and cisplatin, whereas 13 (28.2%) patients received paclitaxel, ifosfamide and cisplatin regimen and 7 (15.2%) patients received GemOx regimen as the second-line chemotherapy. Median OS was observed to be 33.97 months and median progression-free survival was 29.01 months. Second-line chemotherapy in testicular germ cell tumours can result in long-term disease control and all patients who are fit to tolerate second-line therapy should be offered it. Patients with relapsed seminoma did better than relapsed non-seminomatous germ cell tumours.
Sections du résumé
Background
UNASSIGNED
Malignant testicular neoplasms constitute about 1% of all cancers in males. This is one of the most common tumours in adolescents and young adult males. After the introduction of cisplatin-based chemotherapy, the survival of germ cell tumour patients, even those with poor prognostic risk factors, has significantly improved over the years. Second-line chemotherapy in patients who have progressed over the first-line cisplatin-based chemotherapy has shown convincing 5 years of overall survival (OS).
Methodology
UNASSIGNED
This study is a retrospective analysis of testicular cancer patients from 2014 to 2020 who have received salvage chemotherapy treatment at Tata Memorial Centre. Patient demographics, tumour characteristics and treatment details were recorded in a specific format, and progression-free survival and OS were analysed along with response to therapy.
Results
UNASSIGNED
A total of 46 testicular cancer patients from 2014 to 2020, who received second-line chemotherapy, were analysed from the database maintained at our hospital. The median age at diagnosis was 29.5 (18-60) years. Most of the patients (30, 65.2%) presented with lung metastasis and 11 (23.9%) patients with liver metastasis. Most of the patients (21, 45.6%) received vinblastine, ifosfamide and cisplatin, whereas 13 (28.2%) patients received paclitaxel, ifosfamide and cisplatin regimen and 7 (15.2%) patients received GemOx regimen as the second-line chemotherapy. Median OS was observed to be 33.97 months and median progression-free survival was 29.01 months.
Conclusion
UNASSIGNED
Second-line chemotherapy in testicular germ cell tumours can result in long-term disease control and all patients who are fit to tolerate second-line therapy should be offered it. Patients with relapsed seminoma did better than relapsed non-seminomatous germ cell tumours.
Identifiants
pubmed: 36072230
doi: 10.3332/ecancer.2022.1408
pii: can-16-1408
pmc: PMC9377817
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1408Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
None.
Références
Hematol Oncol Clin North Am. 2011 Jun;25(3):557-76, viii -ix
pubmed: 21570609
Cancer. 1996 Mar 15;77(6):1193-7
pubmed: 8635143
J Clin Oncol. 1998 Jul;16(7):2500-4
pubmed: 9667270
Ann Oncol. 2010 Apr;21(4):820-825
pubmed: 19822531
J Clin Oncol. 2003 Jan 1;21(1):113-22
pubmed: 12506179
Indian J Cancer. 2017 Apr-Jun;54(2):415-420
pubmed: 29469069
J Clin Oncol. 1996 Oct;14(10):2638-45
pubmed: 8874322
J Clin Oncol. 1995 May;13(5):1170-6
pubmed: 7537800
J Clin Oncol. 2006 Dec 10;24(35):5493-502
pubmed: 17158534
Adv Urol. 2018 Mar 15;2018:7272541
pubmed: 29736168
J Clin Oncol. 1997 Jul;15(7):2559-63
pubmed: 9215825
Oncol Res Treat. 2018;41(6):365-369
pubmed: 29843143
Ann Oncol. 2005 Jul;16(7):1152-9
pubmed: 15928070